Delaying mitotic exit downregulates FLIP expression and strongly sensitizes tumor cells to TRAIL

Oncogene

Volumn 34, Issue 5, 2015, Pages 661-669

  Sanchez Perez T ^a,b   Medema, R H ^b   Lopez Rivas A ^a  

^a CSIC   (Spain)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

apoptosis; FLIP; mitotic exit; TRAIL; tumor cells

Indexed keywords

CELL CYCLE PROTEIN 20; CYCLIN B; FLICE INHIBITORY PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTIMITOTIC AGENT; CDC20 PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; DOWN REGULATION; MITOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR CELL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PATHOLOGY; TUMOR CELL LINE;

ANTIMITOTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CDC20 PROTEINS; CELL LINE, TUMOR; CYCLIN B; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84927170031     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.601     Document Type: Article

References (40)

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162. DOI: 10.1172/JCI6926
2. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163. DOI: 10.1038/5517
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682. DOI: 10.1016/1074-7613(95)90057-8
4. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7: 1001–1012. DOI: 10.1038/nrd2637
5. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008; 118: 100–110. DOI: 10.1172/JCI33061
6. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833–2840.
7. Palacios C, Yerbes R, Lopez-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 2006; 66: 8858–8869. DOI: 10.1158/0008-5472.CAN-06-0808
8. Sanchez-Perez T, Ortiz-Ferron G, Lopez-Rivas A. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ 2010; 17: 883–894. DOI: 10.1038/cdd.2009.176
9. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747–2753.
10. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241–253. DOI: 10.1038/35008667
11. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599–609. DOI: 10.1016/S1074-7613(00)80211-3
12. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195. DOI: 10.1038/40657
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674. DOI: 10.1016/j.cell.2011.02.013
14. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253–265. DOI: 10.1038/nrc1317
15. Janssen A, Medema RH. Mitosis as an anti-cancer target. Oncogene 2011; 30: 2799–2809. DOI: 10.1038/onc.2011.30
16. Rath O, Kozielski F. Kinesins and cancer. Nat Rev Cancer 2012; 12: 527–539. DOI: 10.1038/nrc3310
17. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005; 8: 7–12. DOI: 10.1016/j.ccr.2005.06.011
18. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14: 111–122. DOI: 10.1016/j.ccr.2008.07.002
19. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006; 16: 1194–1200. DOI: 10.1016/j.cub.2006.04.043
20. Huang HC, Shi J, Orth JD, Mitchison TJ. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009; 16: 347–358. DOI: 10.1016/j.ccr.2009.08.020
21. Manchado E, Guillamot M, de Carcer G, Eguren M, Trickey M, Garcia-Higuera I et al. Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta phosphatase. Cancer Cell 2010; 18: 641–654. DOI: 10.1016/j.ccr.2010.10.028
22. Santaguida S, Tighe A, D'Alise AM, Taylor SS, Musacchio A. Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol 2010; 190: 73–87. DOI: 10.1083/jcb.201001036
23. Abrieu A, Magnaghi-Jaulin L, Kahana JA, Peter M, Castro A, Vigneron S et al. Mps1 is a kinetochore-associated kinase essential for the vertebrate mitotic checkpoint. Cell 2001; 106: 83–93. DOI: 10.1016/S0092-8674(01)00410-X
24. Tighe A, Staples O, Taylor S. Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores. J Cell Biol 2008; 181: 893–901. DOI: 10.1083/jcb.200712028
25. Wasch R, Cross FR. APC-dependent proteolysis of the mitotic cyclin Clb2 is essential for mitotic exit. Nature 2002; 418: 556–562. DOI: 10.1038/nature00856
26. Chang DC, Xu N, Luo KQ. Degradation of cyclin B is required for the onset of anaphase in Mammalian cells. J Biol Chem 2003; 278: 37865–37873. DOI: 10.1074/jbc.M306376200
27. Holloway SL, Glotzer M, King RW, Murray AW. Anaphase is initiated by proteolysis rather than by the inactivation of maturation-promoting factor. Cell 1993; 73: 1393–1402. DOI: 10.1016/0092-8674(93)90364-V
28. Piao X, Komazawa-Sakon S, Nishina T, Koike M, Piao JH, Ehlken H et al. c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis. Sci Signal 2012; 5: ra93. DOI: 10.1126/scisignal.2003558
29. Allan LA, Clarke PR. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 2007; 26: 301–310. DOI: 10.1016/j.molcel.2007.03.019
30. Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 2010; 29: 2407–2420. DOI: 10.1038/emboj.2010.112
31. Matthess Y, Raab M, Sanhaji M, Lavrik IN, Strebhardt K. Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol 2010; 30: 5726–5740. DOI: 10.1128/MCB.00731-10
32. Terrano DT, Upreti M, Chambers TC. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 2010; 30: 640–656. DOI: 10.1128/MCB.00882-09
33. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110–114. DOI: 10.1038/nature09779
34. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124: 601–613. DOI: 10.1016/j.cell.2006.01.021
35. Gottesfeld JM, Forbes DJ. Mitotic repression of the transcriptional machinery. Trends Biochem Sci 1997; 22: 197–202. DOI: 10.1016/S0968-0004(97)01045-1
36. Pyronnet S, Dostie J, Sonenberg N. Suppression of cap-dependent translation in mitosis. Genes Dev 2001; 15: 2083–2093. DOI: 10.1101/gad.889201
37. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56: 816–825.
38. Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 2010; 18: 382–395. DOI: 10.1016/j.ccr.2010.08.010
39. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25417–25420. DOI: 10.1074/jbc.272.41.25417
40. Ruiz-Ruiz C, Lopez-Rivas A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem J 2002; 365: 825–832. DOI: 10.1042/bj20020184